Mesenchymal stem cell therapy for cartilage repair (Medipost)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameMesenchymal stem cell therapy for cartilage repair (Medipost)
Drug Alias Name克帝思坦CartistemSMUP-IA-01
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionCartilage replacementsCell replacements
TargetsNot applicable
Therapy Area/IndicationsOsteoarthritis, KneeOsteoarthritisCartilage Diseases +[4] 
Global Approved IndicationsOsteoarthritisCartilage Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMedipost Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMedipost Co LtdMedipost IncHyundai Bioland
Inactive CompaniesN/A
Active IndicationsOsteoarthritis, KneeOsteoarthritisCartilage Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeV03AX
Related LinksN/A